Ascendis

Ascendis company information, Employees & Contact Information

Explore related pages

Related company profiles:

Established in 1997, ASCENDIS is the largest training and organizational development company in Romania and Republic of Moldova, with a team of 70 consultants and facilitators, a portfolio of more than 500 clients and over 7,000 days of training, assessment centers and team building delivered in the last three years.

Company Details

Employees
157
Founded
-
Address
Bd. Ion Ionescu De La Brad, 2b, Sector 1, Bucuresti,bucharest 013813,romania
Phone
40-21-2066429
Email
of****@****ndis.ro
Industry
Education Management
HQ
Bucuresti, Bucharest
Looking for a particular Ascendis employee's phone or email?

Ascendis Questions

News

Ascendis Skids as FDA Detects Death in Patient Formerly on Yorvipath - BioSpace

Ascendis Skids as FDA Detects Death in Patient Formerly on Yorvipath BioSpace

Ascendis Pharma Reports Second Quarter 2025 Financial Results - Yahoo Finance

Ascendis Pharma Reports Second Quarter 2025 Financial Results Yahoo Finance

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 - GlobeNewswire

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 GlobeNewswire

Ascendis reports interim analysis outcomes from achondroplasia trial - Clinical Trials Arena

Ascendis reports interim analysis outcomes from achondroplasia trial Clinical Trials Arena

Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade (ASND) - Seeking Alpha

Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade (ASND) Seeking Alpha

Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace

Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause BioSpace

Ascendis Pharma Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Ascendis Pharma Second Quarter 2025 Earnings: Beats Expectations Yahoo Finance

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) Seeking Alpha

Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs - BioPharma Dive

Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs BioPharma Dive

Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist - Fierce Biotech

Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist Fierce Biotech

Ascendis Pharma A/S (NASDAQ:ASND): Is Breakeven Near? - Yahoo Finance

Ascendis Pharma A/S (NASDAQ:ASND): Is Breakeven Near? Yahoo Finance

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results GlobeNewswire

Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis - BioSpace

Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis BioSpace

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency - GlobeNewswire

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency GlobeNewswire

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference - Yahoo Finance

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference Yahoo Finance

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 - Yahoo Finance

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 Yahoo Finance

Ascendis Pharma Reports First Quarter 2025 Financial Results - GlobeNewswire

Ascendis Pharma Reports First Quarter 2025 Financial Results GlobeNewswire

Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment - Yahoo Finance

Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment Yahoo Finance

Ascendis Submits Marketing Authorisation Application to the - GlobeNewswire

Ascendis Submits Marketing Authorisation Application to the GlobeNewswire

FDA approves Ascendis’ Skytrofa - The Pharma Letter

FDA approves Ascendis’ Skytrofa The Pharma Letter

Ascendis's YORVIPATH gets FDA approval for hypoparathyroidism - Pharmaceutical Technology

Ascendis's YORVIPATH gets FDA approval for hypoparathyroidism Pharmaceutical Technology

Ascendis trial data piles pressure on BioMarin - BioPharma Dive

Ascendis trial data piles pressure on BioMarin BioPharma Dive

Biotech Leader Ascendis Pharma Set for Key Presentation at 2025 Wells Fargo Healthcare Conference - Stock Titan

Biotech Leader Ascendis Pharma Set for Key Presentation at 2025 Wells Fargo Healthcare Conference Stock Titan

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 - GlobeNewswire

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 GlobeNewswire

Ascendis Pharma Q2 2025 Earnings Call: Key Financial Results Coming August 7 After Market Close - Stock Titan

Ascendis Pharma Q2 2025 Earnings Call: Key Financial Results Coming August 7 After Market Close Stock Titan

Ascendis seeks European approval for dwarfism drug - medwatch.com

Ascendis seeks European approval for dwarfism drug medwatch.com

FDA approves Ascendis drug for rare endocrine condition - BioPharma Dive

FDA approves Ascendis drug for rare endocrine condition BioPharma Dive

Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath - Fierce Pharma

Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath Fierce Pharma

Ascendis' dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin - Fierce Biotech

Ascendis' dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin Fierce Biotech

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency - MedCity News

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency MedCity News

Ascendis Consulting Accelerates Growth with Pencilz Labs Merger - PRWeb

Ascendis Consulting Accelerates Growth with Pencilz Labs Merger PRWeb

Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug - PMLiVE

Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug PMLiVE

Another delay for Ascendis' hormone therapy as FDA extends review by 3 months - Fierce Pharma

Another delay for Ascendis' hormone therapy as FDA extends review by 3 months Fierce Pharma

Ascendis spins out new ophthalmology biotech Eyconis, gaining equity and biobucks - Fierce Biotech

Ascendis spins out new ophthalmology biotech Eyconis, gaining equity and biobucks Fierce Biotech

FDA turns back Ascendis' hormone drug over manufacturing issues - Fierce Pharma

FDA turns back Ascendis' hormone drug over manufacturing issues Fierce Pharma

Why Ascendis Pharma Stock Tumbled by 11% Today - The Motley Fool

Why Ascendis Pharma Stock Tumbled by 11% Today The Motley Fool

An Update On Ascendis Pharma's Path To Profitability (NASDAQ:ASND) - Seeking Alpha

An Update On Ascendis Pharma's Path To Profitability (NASDAQ:ASND) Seeking Alpha

Ascendis sells Japanese rights to Skytrofa and two other hormone drugs for $70M upfront - Fierce Biotech

Ascendis sells Japanese rights to Skytrofa and two other hormone drugs for $70M upfront Fierce Biotech

Why This Small Biotech Is Hammering BioMarin Today - Investor's Business Daily

Why This Small Biotech Is Hammering BioMarin Today Investor's Business Daily

After manufacturing setback at FDA, Ascendis strikes $150M royalty deal on its first commercial drug - Fierce Pharma

After manufacturing setback at FDA, Ascendis strikes $150M royalty deal on its first commercial drug Fierce Pharma

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan - GlobeNewswire

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan GlobeNewswire

From collapse to comeback at Ascendis Health: Lessons to learn says CEO Carl Neethling - IOL

From collapse to comeback at Ascendis Health: Lessons to learn says CEO Carl Neethling IOL

Ascendis Pharma A/S Announces U.S. Food and Drug - GlobeNewswire

Ascendis Pharma A/S Announces U.S. Food and Drug GlobeNewswire

Ascendis Pharma A/S Announces Extension of U.S. Food and - GlobeNewswire

Ascendis Pharma A/S Announces Extension of U.S. Food and GlobeNewswire

Big blow for Ascendis Health directors - Daily Investor

Big blow for Ascendis Health directors Daily Investor

Ascendis Health takeover investigated - Daily Investor

Ascendis Health takeover investigated Daily Investor

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant